Design and Evaluation of a 68 Ga-Labeled Dimeric Cyclic Peptide as a Large-Volume Linker Strategy for Balancing Affinity and Retention in CXCR4-Targeted PET Imaging
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Jingjing Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: R&D Department, HTA Co., Ltd, Beijing 102413, China. Hauptthemen laut MEDLINE: Receptors, CXCR4, Peptides, Cyclic, Gallium Radioisotopes, Radiopharmaceuticals. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Beijing Science and Technology Planning Project.
Abstract (Originalsprache)
CXCR4 is overexpressed in various malignancies and represents an attractive target for PET imaging. However, currently available peptide-based tracers often exhibit rapid clearance and a narrow imaging window, which limit their clinical implication. Here, we report the design and preclinical characterization of a 68Ga-labeled dimeric cyclic peptide, implementing a large-volume linker strategy aimed at achieving an optimized balance between receptor affinity and tumor retention for CXCR4-targeted PET imaging. The tracer was synthesized, radiolabeled with the 68Ga3+ ion, and evaluated for radiochemical purity. In vitro stability, binding affinity, CXCR4-specific cellular uptake, pharmacokinetics, biodistribution, and PET/CT imaging were also assessed. The tracer showed high radiochemical purity and excellent stability. Although its binding affinity was moderate (IC50 = 161.5 nM), the tracer exhibited clear CXCR4-specific uptake and sustained tumor retention, with PET-derived tumor uptake of 3.4-3.8%ID/g between 30 and 240 min and tumor-to-muscle ratios increasing from ∼10 to ∼62 over the same period. However, notable hepatic uptake was observed, which may be attributed to the peptide size and moderate hydrophobicity. Further structural optimization such as PEGylation or scaffold minimization may reduce hepatic uptake and enhance the clinical applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R&D Department, HTA Co., Ltd, Beijing 102413, China.
- Institute of Nuclear Technology and Applications, China Institute of Atomic Energy, Beijing 102413, China.
- State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China.
- China Institute for Radiation Protection, Taiyuan 030006, China.
Förderung
- Beijing Science and Technology Planning Project
Zitieren
APA
Yu, J., Zhou, X., Pei, Y., Gao, F., Sun, M., Qiu, S., He, Z., Gao, J., Qin, X., Zhao, H., Wen, K., Wang, G., & Shen, L. (2026). Design and Evaluation of a 68 Ga-Labeled Dimeric Cyclic Peptide as a Large-Volume Linker Strategy for Balancing Affinity and Retention in CXCR4-Targeted PET Imaging. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01277
Vancouver
Yu J, Zhou X, Pei Y, Gao F, Sun M, Qiu S, et al. Design and Evaluation of a 68 Ga-Labeled Dimeric Cyclic Peptide as a Large-Volume Linker Strategy for Balancing Affinity and Retention in CXCR4-Targeted PET Imaging. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01277
BibTeX
@article{Yu2026,
author = {Yu, Jingjing and Zhou, Xu and Pei, Yang and Gao, Fei and Sun, Mingyue and Qiu, Shanshan and He, Zhexin and Gao, Jie and Qin, Xiangyu and Zhao, Hailong and Wen, Kai and Wang, Guobao and Shen, Langtao},
title = {Design and Evaluation of a 68 Ga-Labeled Dimeric Cyclic Peptide as a Large-Volume Linker Strategy for Balancing Affinity and Retention in CXCR4-Targeted PET Imaging},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01277}
}
EUVIMED